Sientra Announces First Shipment of Viality Fat Transfer System; New Preliminary Data

Sientra announced that it has begun commercial shipping of its Viality with AuraClens fat transfer system.

The company also announced the release of preliminary results from its ongoing, multicenter, long-term volume retention clinical study with Viality. These results show over 80% volume retention at both the 3- and 6-month timepoints, making Viality the only system to have clinically demonstrated such high levels of retention, according to a company news release.

“The promising results showcased in this preliminary data mirrors what I am seeing clinically with the patients I have treated with Viality to-date,” board-certified plastic surgeon and clinical study investigator, Sachin M. Shridharani, MD, FACS, said in the news release. “Fat transfer has been gaining popularity for the past decade, and with Viality, Sientra has not only contributed to an unmet market need through superior fat retention rates, but allows me to offer my patients predictable outcomes, with the natural results they are looking for.”

Based on the preliminary results, with 68 patients* enrolled, the clinical study shows over 80% volume retention at both 3- and 6-months post breast augmentation and reconstruction. In addition, volume changes from 3 to 6 months were on average only 3.59%, indicating the long-term viability of fat transfer when using Viality, according to Sientra.

The full preliminary results are now available here. Sientra will continue to develop the data within the ongoing clinical study.

*Not all patients in the study had reached 3 and 6 month timepoints when preliminary results were released